Furthermore, PD-1+ IFN-γ+ cell percentages of CD8+ T cells at baseline correlate with PFS in patients with NSCLC and may be an independent prognostic factor for anti–PD-1 therapy. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.